Outcomes following intolerance to calcineurin inhibitor-based graft-versus-host disease prophylaxis in children after allogeneic hematopoietic cell transplantation

被引：0

作者：

Wu, Diana ^{[1
]}

Li, Ying ^{[2
]}

Bi, Yu ^{[3
]}

Lannom, Trevor M. ^{[1
]}

Ward, Deborah A. ^{[1
]}

Qudeimat, Amr ^{[2
,4
]}

Madden, Renee M. ^{[2
]}

Sharma, Akshay ^{[2
]}

Epperly, Rebecca ^{[2
,4
]}

Mamcarz, Ewelina ^{[2
,4
]}

Talleur, Aimee ^{[2
,4
]}

Naik, Swati ^{[2
,4
]}

Selukar, Subodh ^{[3
]}

Triplett, Brandon ^{[2
,4
]}

Srinivasan, Ashok ^{[2
,4
,5
]}

机构：

[1] St Jude Childrens Res Hosp, Dept Pharm & Pharmaceut Sci, Memphis, TN USA

[2] St Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, Memphis, TN USA

[3] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN USA

[4] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN USA

[5] St Jude Childrens Res Hosp, Dept Bone Marrow Transplantat & Cellular Therapy, 262 Danny Thomas Pl,MS1130, Memphis, TN 38105 USA

来源：

PEDIATRIC BLOOD & CANCER | 2023年 / 70卷 / 09期

关键词：

calcineurin inhibitors; pediatric; transplantation; GINGIVAL HYPERPLASIA; CYCLOSPORINE; TACROLIMUS; BLOOD;

D O I：

10.1002/pbc.30517

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Calcineurin inhibitors (CNI), cyclosporine and tacrolimus, are commonly used for pharmacologic prophylaxis of graft-versus-host disease after allogeneic hematopoietic cell transplantation (HCT). Unfortunately, their use is associated with significant toxicities. While intolerance to CNI is well defined, there is very little information on how they impact outcomes after HCT in children. Our retrospective study in a cohort of 82 children shows a high intolerance rate of 39% in this population associated with lower event-free survival and a higher transplant-related mortality.

引用

页数：4

共 50 条

[1] Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Mirza, Abu-Sayeef
Tandon, Ankita
Jenneman, Dakota
Cao, Shu
Brimer, Thomas
Kumar, Ambuj
Kidd, Michelle
Khimani, Farhad
Faramand, Rawan
Mishra, Asmita
Liu, Hien
Nishihori, Taiga
Perez, Lia
Lazaryan, Aleksandr
Bejanyan, Nelli
Nieder, Michael
Anasetti, Claudio
Pidala, Joseph
Elmariah, Hany
[J]. TRANSPLANTATION AND CELLULAR THERAPY, 2022, 28 (04): : 185.e1 - 185.e7
[2] Corticosteroids as graft-versus-host disease prophylaxis for allogeneic hematopoietic cell transplant recipients with calcineurin inhibitor intolerance
Puckrin, Robert
Kwan, Alex Chi Fung
Blosser, Nikki
Leyshon, Catherine
Duggan, Peter
Daly, Andrew
Zepeda, Victor
Stewart, Douglas
Chaudhry, Ahsan
Storek, Jan
Jamani, Kareem
[J]. CYTOTHERAPY, 2023, 25 (10) : 1101 - 1106
[3] Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant
Mirza, Sayeef
Tandon, Ankita
Jenneman, Dakota
Cao, Shu
Kumar, Ambuj
Kidd, Michelle R.
Khimani, Farhad
Mishra, Asmita
Liu, Hien D.
Nishihori, Taiga
Perez, Lia
Bejanyan, Nelli
Pidala, Joseph
Nieder, Michael
Elmariah, Hany
[J]. BLOOD, 2019, 134
[4] Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation
Chhabra, Saurabh
Visotcky, Alexis
Pasquini, Marcelo C.
Zhu, Fenlu
Tang, Xiaoying
Zhang, Mei-Jie
Thompson, Robert
Abedin, Sameem
D'Souza, Anita
Dhakal, Binod
Drobyski, William R.
Fenske, Timothy S.
Jerkins, James H.
Rizzo, J. Douglas
Runaas, Lyndsey
Saber, Wael
Shah, Nirav N.
Shaw, Bronwen E.
Horowitz, Mary M.
Hari, Parameswaran N.
Hamadani, Mehdi
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (10) : 1876 - 1885
[5] NEUROLOGIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CALCINEURIN-FREE GRAFT-VERSUS-HOST DISEASE PROPHYLAXIS
Balaguer Rosello, Aitana
Garcia Gil-Perotin, Sara
Montoro, Juan
Villalba, Marta
Facal, Ana
Guerreiro, Manuel
Chorao, Pedro
Louro, Alberto
Granados, Pablo
De La Rubia, Javier
Sanz, Jaime
[J]. BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 542 - 543
[6] Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation
Chhabra, Saurabh
Jerkins, James H.
Monahan, Kathleen
Szabo, Aniko
Shah, Nirav N.
Abedin, Sameem
Runaas, Lyndsey
Fenske, Timothy S.
Pasquini, Marcelo C.
Shaw, Bronwen E.
Drobyski, William R.
Saber, Wael
D'Souza, Anita
Dhakal, Binod
Mohan, Meera
Longo, Walter
Hamadani, Mehdi
[J]. BONE MARROW TRANSPLANTATION, 2024, 59 (03) : 373 - 379
[7] Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation
Saurabh Chhabra
James H. Jerkins
Kathleen Monahan
Aniko Szabo
Nirav N. Shah
Sameem Abedin
Lyndsey Runaas
Timothy S. Fenske
Marcelo C. Pasquini
Bronwen E. Shaw
William R. Drobyski
Wael Saber
Anita D’Souza
Binod Dhakal
Meera Mohan
Walter Longo
Mehdi Hamadani
[J]. Bone Marrow Transplantation, 2024, 59 : 373 - 379
[8] VORICONAZOLE PROPHYLAXIS FOR CHILDREN AND ADOLESCENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE FOLLOWING HEMATOPOIETIC CELL TRANSPLANTATION
Sano, Hirozumi
Matsushima, Satoru
Hori, Daiki
Yanagi, Masato
Kobayashi, Ryoji
[J]. PEDIATRIC BLOOD & CANCER, 2024, 71 : S55 - S55
[9] Reduced Incidence of Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation with Calcineurin-Free Graft-versus-Host Disease Prophylaxis
Balaguer-Rosello, Aitana
Gil-Perotin, Sara
Montoro, Juan
Bataller, Luis
Lamas, Brais
Villalba, Marta
Facal, Ana
Guerreiro, Manuel
Chorao, Pedro
Gomez, Ines
Solves, Pilar
Louro, Alberto
Rubia, Javier de la
Sanz, Miguel Angel
Sanz, Jaime
[J]. TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (10): : 610.e1 - 610.e12
[10] Antithymocyte Globulin for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation
Mohty, Mohamad
Malard, Florent
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (36) : 3993 - +

← 1 2 3 4 5 →